Skip to search formSkip to main contentSkip to account menu

Fumaderm

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Objectives: Therapeutic options in progressive forms of multiple sclerosis (MS) are still limited. Dimethyl fumarate (DMF) has… 
2014
2014
Fumaric acid, first applied topically in psoriasis, has also been used orally since the mid-1980s. A preparation of dimethyl… 
2014
2014
Background: Psoriasis is one of the most common inflammatory skin disorders. There are only limited data on systemic treatment in… 
2012
2012
Overexpression of antimicrobial peptides and proteins (AMPs) such as human β-defensin-2 (hBD2), LL37, and psoriasin has… 
2011
2011
Ulrich Mrowietz, Peter Altmeyer, Matthias Augustin, Wolf-Henning Boehncke, Bernd Bonnekoh, Yvonne Frambach, Thilo Gambichler… 
Review
2009
Review
2009
1.1 Allgemeine Merkmale der Psoriasis Die Psoriasis ist eine der häufigsten chronisch entzündlichen Hauterkrankungen. In… 
2004
2004
ZusammenfassungEine 61-jährige Patientin mit kutaner Sarkoidose wurde systemisch über 12 Monate mit Fumarsäureester (Fumaderm… 
1997
1997
Monomethylfumarate (MMF), the most active metabolite of the new antipsoriasis drug FumadermR, stimulates an anti‐inflammatory… 
1996
1996
ZusammenfassungSeit mehr als 30 Jahren wird der therapeutische Effekt sowie das Nebenwirkungsspektrum der Fumarsäurederivate in… 
Highly Cited
1995
Highly Cited
1995
Objective The aim of this study was to assess the clinical efficacy of long‐term (> 6 months) oral fumarate maintenance treatment…